Immunome (NASDAQ:IMNM) Stock, Quote.Headers.trade-ideas

Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Stocks Photo by Jirapong Manustrong on Shutterstock

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ACDC

ASTC

IMNM

Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying

Bull and bear stock market index

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Intraday Update

Analyst Ratings

ETFs

$BTC

AMZN

CATX

SPDR Dow Jones Industrial Average ETF Trust

GOLD

NKLA

SMTC

XLRE

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What&#39;s Driving Markets Thursday?

Penny Stocks

Small Cap

Movers

ALAB

ANNX

DAVE

DNTH

LAAC

MRNO

NOVA

OCGN

SMLP

TCRX

TLRY

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

Immunome Inc

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Cybertruck lead engineer Wes Morrill on Tuesday expressed disappointment over Grok-generated images of the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck">stainless steel truck.</a>
What Happened: &#8220;I would wager X has the highest concentration of Cybertruck training images of any social media. So it&#8217;s extra disappointing when Grok absolutely nails the design aesthetic but has no clue what a Cybertruck looks like&#8230;,&#8221; Morrill wrote on social media platform X. 
The engineer also shared images of the Cybertruck generated by Grok, all of which show different forms but none resembling the Cybertruck&#8217;s angular design. While some images generated by Grok show the Cybertruck as a roadster vehicle, others show it as a sports car. None of them, according to Morrill, &#8220;quite hit the mark.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">More awesome designs that didn&#39;t quite hit the mark&#8230; <a href="https://t.co/BpTZvOQmrb">pic.twitter.com/BpTZvOQmrb</a>
&mdash; Wes (@wmorrill3) <a href="https://twitter.com/wmorrill3/status/1838464108355809474?ref_src=twsrc%5Etfw">September 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Grok is the chatbot developed by Elon Musk&#8216;s artificial intelligence startup xAI as a rival to OpenAI&#8217;s ChatGPT. It is integrated with the billionaire&#8217;s social media platform X.
The Cybertruck, meanwhile, is the latest offering from Tesla, the EV company of which Musk is CEO.
The Cybertruck is known for its angular, stainless steel exterior, setting it apart from other vehicles. The unusual design, coupled with its high price point, has also made it a <a href="https://www.benzinga.com/general/entertainment/24/09/40926236/kim-kardashian-debuts-custom-metallic-silver-cybertruck-will-elon-musk-approve-the-celebrit">celebrity pick</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40979752/elon-musk-says-buses-wont-be-needed-once-tesla-robotaxis-start-operating-will-take-people-point-" target="_blank" rel="noreferrer noopener">Elon Musk Says Buses Won&#8217;t Be Needed Once Tesla Robotaxis Start Operating: ‘Will Take People Point To Point For A Similar Cost&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Elon Musk's Grok AI Chatbot Has 'No Clue' What Tesla's Cybertruck Looks Like: Senior Exec Calls It 'Extra Disappointing'

FAAS

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Wedbush analyst David Chiaverini upgrades Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) from Neutral to Outperform and raises the price target from $75 to $90.

Upgrades

Price Target

Wedbush Upgrades Prosperity Bancshares to Outperform, Raises Price Target to $90

OCTO

Eightco Receives Formal Notice From Nasdaq That Company Has Regained Compliance With Minimum Bid Price Requirement

Wedbush analyst David Chiaverini upgrades Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) from Neutral to Outperform and raises the price target from $28 to $31.

COLB

Wedbush Upgrades Columbia Banking System to Outperform, Raises Price Target to $31

Google Cloud today announced an expanded strategic partnership with Snap Inc. to power generative AI experiences within My AI, Snapchat's AI-powered chatbot and one of the largest consumer chatbots available today.
Snapchat will leverage the strong multimodal capabilities of Gemini on Vertex AI, particularly the technology's ability to understand and operate across different types of information like text, audio, image, video, and code, to offer more engaging and innovative features for the Snapchat community through My AI. For example, with Gemini on Vertex AI integrated into the app, Snapchatters can ask My AI to translate a photo of a street sign while traveling abroad, or take a video of different snack offerings to ask which one is the healthiest option.

GOOG

GOOGL

SNAP

Snap Partners with Google Cloud to Power Multi-Modal Generative AI Experiences Within its My AI Chatbot

NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively.

Ginkgo Bioworks Enters Its New Partnership With NOVUS International

Wedbush analyst David Chiaverini upgrades Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) from Neutral to Outperform and raises the price target from $52 to $75.

Wedbush Upgrades Comerica to Outperform, Raises Price Target to $75

Pebblebrook Hotel Trust Prices Private Placement Of $400M Of 6.375% Senior Notes Due 2029

Village Farms International Announced That It Has Acquired The Remaining Equity Ownership Interest In Leli Holland To Increase Equity Ownership To 100% From 85%

Overall the updated analysis reveals a 56% objective response rate (ORR) in patients treated with LODER, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable. This marks a significant step forward in potentially improving surgical outcomes for LAPC patients.

Biotech

Health Care

General

SLXN

Silexion Therapeutics Announced New Findings From Its Phase 2 Trial Of LODER In Patients With Non-resectable Locally Advanced Pancreatic Cancer (LAPC) Which Bear KRAS G12D Or G12V Mutation-Filing

GOEV

Canoo Says It Launched Commercial Operations And Activation Center In The United Kingdom;  Expansion Poised To Capitalize On The Strong Demand In The Light Commercial Vehicle Market

Macro Economic Events

iShares MSCI Israel Capped Investable Market Index Fund

White House's Kirby Said Americans Should Leave While Commercial Travel Is Still Available Amid Israel-Lebanon Conflict

CEVA

CEVA Says It Inked Pact With Edge Impulse To Enable Faster, Easier Development Of Edge AI Applications

Italian automaker Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) is reportedly looking for a new CEO to replace Carlos Tavares.
What Happened: Tavares took the helm of the company in 2021. The company <a href="https://apnews.com/article/stellantis-jeep-ram-ceo-carlos-tavares-6a882961eb47c581e6105d2bc473f57c">told</a> Associated Press on Monday that the look out for a new CEO is part of the normal process of determining leadership succession.
Tavares&#8217; contract is set to expire in 2026, AP reported. There is also a possibility that Tavares will stay in the role for longer, it added.
Earlier this month, President of U.S. Stellantis National Dealer Council (NDC) Kevin Farrish <a href="https://www.benzinga.com/news/24/09/40827607/stellantis-fires-back-at-us-dealer-councils-allegation-of-short-term-decision-making-carmaker-says-p" target="_blank" rel="noreferrer noopener">wrote to company CEO</a> Tavares, accusing him of &#8220;short-term decision-making&#8221; and urged that the CEO spend more to clear older inventory.
Tavares&#8217; decisions, the NDC President said, ended up shrinking the company&#8217;s market share and hurting its many brands. Stellantis, however, said that it takes &#8220;absolute exception&#8221; to the letter, and termed it a &#8220;public personal attack.&#8221;
The company has also faced flack from the United Auto Workers (UAW) union. Last week, <a href="https://www.benzinga.com/news/24/09/40996835/xpeng-touches-production-milestone-of-500k-evs-heres-how-many-electric-cars-the-chinese-company-has">UAW</a> said that it <a href="https://www.benzinga.com/news/24/09/40894503/uaw-files-nlrb-complaint-against-stellantis-over-alleged-contract-violations-says-it-intends-to-make" target="_blank" rel="noreferrer noopener">filed federal unfair labor practice charges</a> at the National Labor Relations Board (NLRB) against Stellantis for alleged violation of the <a href="https://www.benzinga.com/news/23/11/35530931/stellantis-weathered-uaw-strikes-better-than-gm-and-ford-with-less-financial-toll-cfo" target="_blank" rel="noreferrer noopener">labor contract entered into last year</a>.
The union alleges that Stellantis is attempting to move the production of the Dodge Durano SUV out of the U.S. and is also looking to not reopen the idled Belvidere assembly plant in Illinois despite it being promised.
The company, however, said that it has abided with the agreement it entered into last year with the union and will continue to.
Why It Matters: For the first half of 2024, Stellantis reported a 48% fall in net profit to €5.6 billion ($6.22 billion) and a 14% fall in net revenue to €85 billion, owing to a&nbsp;<a href="https://www.benzinga.com/markets/24/06/39477084/stellantis-threatens-to-exit-uk-over-unsustainable-ev-sales-targets-if-this-market-becomes-hostile-f" target="_blank" rel="noreferrer noopener">dip in market share</a>&nbsp;in North America.
"It is an understatement to say that H1 2024 results were disappointing and humbling,"&nbsp;<a href="https://www.benzinga.com/news/earnings/24/07/39959183/stellantis-ceo-earnings-fell-short-of-expectations-expect-20-new-vehicles-this-year" target="_blank" rel="noreferrer noopener">Tavares said</a>&nbsp;at the company's earnings call in July.
&#8220;The Company&#8217;s performance in the first half of 2024 fell short of our expectations, reflecting both a challenging industry context as well as our own operational issues… We have significant work to do, especially in North America, to maximize our long-term potential," he said while also reiterating his personal involvement with the teams in North America to fix the issue.
In the second quarter alone, Stellantis saw its sales in the U.S. fall 21% to 344,993 vehicles.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40996835/xpeng-touches-production-milestone-of-500k-evs-heres-how-many-electric-cars-the-chinese-company-has">XPeng Touches Production Milestone Of 500K EVs: Here&#8217;s How Many Electric Cars The Chinese Company Has Delivered</a></li>
</ul>
Photo courtesy: Shutterstock

STLA

Stellantis Begins Search For New CEO To Succeed Carlos Tavares: Report

FANG

KNTK

Diamondback Energy, Kinetik And EPIC Midstream Announced A Series Of Transactions To Support The Continued Growth And Strengthened Financial Profile Of EPIC Crude Holdings, LP

Contracts

Teledyne FLIR Defense Receives Two Five-Year Requirements Contracts Worth Up To $47M In Total To Provide And Support Nearly Its Entire Range Of Ground Robots To US Government

Raymond James analyst Josh Beck initiates coverage on Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Market Perform rating.

Initiation

CART

Raymond James Initiates Coverage On Maplebear with Market Perform Rating

SVCO

Silvaco Says It Expanded Its Victory TCAD And Digital Twin Modeling Platform To Planar CMOS, FinFET And Advanced CMOS Technologies

Featured presentations include data from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy, findings from the CRESCENDO patient survey underscoring the unmet needs of patients with type 1 narcolepsy, and previously reported data on solriamfetol demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with OSA and narcolepsy.

AXSM

Axsome Therapeutics Announced Seven Presentations On AXS-12 And Solriamfetol At Sleep Europe 2024

Immunome names Tsai as chief technical officer

Immunome: Enthusiasm For New Management Has Faded

Immunome: AL102 And Other Established Protein Targets Could Drive Value

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Immunome (IMNM – Research Report) yesterday. The company's shares closed yesterday at $...

TD Cowen Sticks to Its Buy Rating for Immunome (IMNM)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Immunome (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnm-stock-quote/">IMNM</a>) just reported results for the second quarter of 2024.<ul><li>Immunome reported earnings per share of -60 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company reported revenue of $2.36 million.</li><li>This was 7.29% worse than the analyst estimate for revenue of $2.55 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/imnm-stock-earnings-immunome-for-q2-of-2024/">IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

Immunome GAAP EPS of -$0.60 misses by $0.17, revenue of $2.37M beats by $0.5M

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Immunome (IMNM – Research Report), with a price target of $23....

Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)

Wedbush analyst David Nierengarten assigned a Buy rating to Immunome (IMNM – Research Report) today and set a price target of $33.00. The company's...

Immunome (IMNM) Gets a Buy from Wedbush

Immunome (IMNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Berens from Leer...

Buy Rating Affirmed on Immunome: Promising Clinical Trials and Strategic Growth Prospects

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Immunome (IMNM – Research Report). The company's shares closed...

ABBV

ADXS

NVSEF

SWTX

ZNTL

Press Releases

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Appoints Phil Tsai as Chief Technical Officer

Management

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Nectin Therapeutics Licenses Novel Antibodies to Immunome

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Immunome

Immunome (IMNM) Forecast

Immunome (NASDAQ:IMNM) Stock, Quote.Headers.trade-ideas